Patents by Inventor Chung-Chen Wei

Chung-Chen Wei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7582756
    Abstract: The present invention provides a method to make a pyrrole substituted 2-indolinone compound of the formula
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: September 1, 2009
    Assignees: Sugen, Inc., Pharmacia & Upjohn Company
    Inventors: Huiping Guan, Congxin Liang, Li Sun, Peng Cho Tang, Chung Chen Wei, Tomas Vojkovsky, Qingwu Jin, Paul M. Herrinton, Michael A. Mauragis
  • Patent number: 7572924
    Abstract: The present invention relates to pyrrole substituted-2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: August 11, 2009
    Assignees: Sugen, Inc., Pharmacia & Upjohn Co.
    Inventors: Peng Cho Tang, Todd Anthony Miller, Xiaoyuan Li, Connie Li Sun, Chung Chen Wei, Shahrzad Shirazian, Congxin Liang, Tomas Vojkovsky, Asaad S. Nematalla, Michael Hawley
  • Patent number: 7256189
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: August 14, 2007
    Assignees: Sugen, Inc., Pharmacia & Upjohn Company
    Inventors: Huiping Guan, Congxin Liang, Li Sun, Peng Cho Tang, Chung Chen Wei, Tomas Vojkovsky, Qingwu (Alan) Jin, Paul M. Herrinton, Michael A. Mauragis
  • Patent number: 7214700
    Abstract: The present invention relates to (2-oxindol-3-ylidenyl)acetic acid derivatives which modulate the activity of protein kinases and are therefore useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: May 8, 2007
    Assignee: Sugen Inc.
    Inventors: Chung Chen Wei, Peng Cho Tang
  • Patent number: 7186716
    Abstract: Compounds of Formula I are useful as mediators of protein kinases and have activity as cell proliferation inhibitors: where X, R1–R7 and R9 are as defined herein.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: March 6, 2007
    Assignee: Sugen, Inc.
    Inventors: Chung Chen Wei, Ping Huang, Yi Xia
  • Patent number: 7179910
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: February 20, 2007
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Huiping Guan, Congxin Liang, Li Sun, Peng Cho Tang, Chung Chen Wei, Tomas Vojkovsky, Qingwu (Alan) Jin, Paul M. Herrinton, Michael A. Mauragis
  • Publication number: 20070027149
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Application
    Filed: August 28, 2006
    Publication date: February 1, 2007
    Inventors: Huiping Guan, Congxin Liang, Connie Sun, Peng Cho Tang, Chung Chen Wei, Tomas Vojkovsky, Qingwu Jin, Paul Herrinton, Michael Mauragis
  • Patent number: 7125905
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: October 24, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Peng Cho Tang, Todd A. Miller, Xiaoyuan Li, Li Sun, Chung Chen Wei, Shahrzad Shirazian, Congxin Liang, Tomas Vojkovsky, Asaad S. Nematalla, Michael Hawley
  • Patent number: 7105562
    Abstract: The present invention relates to certain sulfonamido-substituted geometrically restricted indolinones of the formula: wherein R1–R12 and X are variables defined herein. The sulfonamido-substituted geometrically restricted indolinones of the preferred embodiments of the present invention modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: September 12, 2006
    Assignee: Sugen, Inc.
    Inventors: Fang-Jie Zhang, Jingrong Cui, Chung Chen Wei, Peng Cho Tang
  • Patent number: 7053086
    Abstract: The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases (“PKs”), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: May 30, 2006
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Chung Chen Wei, Ping Huang, Jingrong Cui
  • Patent number: 7053114
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: April 5, 2004
    Date of Patent: May 30, 2006
    Assignee: Sugen, Inc.
    Inventors: Connie Li Sun, Chung Chen Wei, Peng Cho Tang, Marcel Koenig, Yong Zhou, Tomas Vojkovsky, Asaad S. Nematalla
  • Publication number: 20050176802
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Application
    Filed: January 4, 2005
    Publication date: August 11, 2005
    Inventors: Peng Cho Tang, Todd Miller, Xiaoyuan Li, Li Sun, Chung Chen Wei, Shahrzad Shirazian, Congxin Liang, Tomas Vojkovsky, Asaad Nematalla, Michael Hawley
  • Patent number: 6908930
    Abstract: This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Particular 4-substituted 7-aza-indolin-2-ones disclosed herein are of Formula 1 and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, X, Y, and Z are defined herein. The invention further relates to pharmaceutical compositions and dosage forms comprising compounds of Formula 1 and to methods of their use for the treatment and/or prevention of diseases such as, but not limited to, cancer.
    Type: Grant
    Filed: July 21, 2003
    Date of Patent: June 21, 2005
    Assignee: Sugen, Inc.
    Inventors: Congxin Liang, Li Sun, Chung Chen Wei, Peng Cho Tang, Gerald McMahon, Klaus Peter Hirth, Jingrong Cui
  • Patent number: 6861418
    Abstract: The present invention relates to 4-arylindolinones, as well as pharmaceutical compositions thereof, capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. The present invention also relates to methods for treating protein kinase related disorders.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: March 1, 2005
    Assignee: Sugen, Inc.
    Inventors: Jingrong Cui, Ruofei Zhang, Hong Shen, Ji Yu Chu, Fang-Jie Zhang, Marcel Koenig, Steven Huy Do, Xiaoyuan Li, Chung Chen Wei, Peng Cho Tang
  • Publication number: 20050038066
    Abstract: The present invention relates to certain sulfonamido-substituted geometrically restricted indolinones of the formula: wherein R1-R12 and X are variables defined herein. The sulfonamido-substituted geometrically restricted indolinones of the preferred embodiments of the present invention modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Application
    Filed: August 5, 2004
    Publication date: February 17, 2005
    Inventors: Fang-Jie Zhang, Jingrong Cui, Chung Chen Wei, Peng Tang
  • Patent number: 6838558
    Abstract: Disclosed are novel pyrazolobenzodiazepines having the formula These compounds are useful in the preparation of the pyrazolobenzodiazepines of formula I, which are useful in the treatment and control of solid tumors.
    Type: Grant
    Filed: April 15, 2002
    Date of Patent: January 4, 2005
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Qingjie Ding, Jin-Jun Liu, Giacomo Pizzolato, Chung-Chen Wei, Peter Michael Wovkulich
  • Patent number: 6797725
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: April 9, 2002
    Date of Patent: September 28, 2004
    Assignee: Sugen, Inc.
    Inventors: Connie Li Sun, Chung Chen Wei, Peng Cho Tang, Marcel Koenig, Yong Zhou, Tomas Vojkovsky, Asaad S. Nematalla
  • Publication number: 20040186161
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Application
    Filed: April 5, 2004
    Publication date: September 23, 2004
    Applicant: Sugen, Inc.
    Inventors: Connie Li Sun, Chung Chen Wei, Peng Cho Tang, Marcel Koenig, Yong Zhou, Tomas Vojkovsky, Asaad S. Nematalla
  • Publication number: 20040157909
    Abstract: The present invention relates to 4-arylindolinones, as well as pharmaceutical compositions thereof, capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. The present invention also relates to methods for treating protein kinase related disorders.
    Type: Application
    Filed: December 16, 2003
    Publication date: August 12, 2004
    Applicant: Sugen, Inc.
    Inventors: Jingrong Cui, Ruofei Zhang, Hong Shen, Ji Yu Chu, Fang-Jie Zhang, Marcel Koenig, Steven Huy Do, Xiaoyuan Li, Chung Chen Wei, Peng Cho Tang
  • Publication number: 20040138255
    Abstract: The invention relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are related to cellular signal transduction, in particular, protein tyrosine phosphatase, and therefore are expected to be useful in the prevention and treatment of disorders associated with abnormal protein tyrosine enzyme related cellular signal transduction such as cancer, diabetes, immuno-modulation, neurologic degenerative diseases, osteoporosis and infectious diseases. The invention also relates to the use of compounds containing fluoromethyl sulfonyl groups as phosphate mimics. These mimics may be used to inhibit, regulate or modulate the activity of a phosphate binding protein in a cell.
    Type: Application
    Filed: July 14, 2003
    Publication date: July 15, 2004
    Applicant: Sugen, Inc.
    Inventors: Ping Huang, Chung Chen Wei, Peng Cho Tang, Congxin (Chris) Liang, John Ramphal, Bahija Jallal, John Biltz, Xiaoyuan (Sharon) Li, Matt Mattson, Gerald McMahon, Marcel Koenig